S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Famous Wall Street Crash System Flashes RED (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Famous Wall Street Crash System Flashes RED (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Famous Wall Street Crash System Flashes RED (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Famous Wall Street Crash System Flashes RED (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Famous Wall Street Crash System Flashes RED (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Famous Wall Street Crash System Flashes RED (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Famous Wall Street Crash System Flashes RED (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Famous Wall Street Crash System Flashes RED (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Famous Wall Street Crash System Flashes RED (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Famous Wall Street Crash System Flashes RED (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Famous Wall Street Crash System Flashes RED (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Famous Wall Street Crash System Flashes RED (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:CABA

Cabaletta Bio (CABA) Stock Forecast, Price & News

$10.09
+0.26 (+2.64%)
(As of 05/31/2023 ET)
Compare
Today's Range
$9.67
$10.09
50-Day Range
$7.10
$13.16
52-Week Range
$0.59
$13.44
Volume
307,414 shs
Average Volume
478,487 shs
Market Capitalization
$316.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.17

Cabaletta Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.4% Upside
$14.17 Price Target
Short Interest
Bearish
12.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$259,820 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

510th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

78th out of 167 stocks


CABA stock logo

About Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Stock News Headlines

Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
10-Q: CABALETTA BIO, INC.
Cabaletta Bio GAAP EPS of -$0.45 beats by $0.02
Recap: Cabaletta Bio Q1 Earnings
Mizuho Securities Sticks to Its Buy Rating for Cabaletta Bio (CABA)
See More Headlines
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Company Calendar

Last Earnings
3/16/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.17
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+40.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-52,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.92 per share

Miscellaneous

Free Float
27,490,000
Market Cap
$316.42 million
Optionable
Not Optionable
Beta
2.54

Key Executives

  • Dr. Steven A. Nichtberger M.D. (Age 61)
    Co-Founder, Chairman, CEO & Pres
    Comp: $904.13k
  • Dr. Gwendolyn K. Binder Ph.D. (Age 47)
    Pres of Science & Technology
    Comp: $654.51k
  • Dr. David J. Chang FACR (Age 59)
    M.D., M.P.H., Chief Medical Officer
    Comp: $656.29k
  • Dr. Michael C. Milone M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Dr. Aimee Payne M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. Anup Marda M.B.A. (Age 45)
    Chief Financial Officer
  • Dr. Samik Basu M.D.
    Chief Scientific Officer
  • Mr. Michael Gerard J.D. (Age 42)
    Gen. Counsel & Sec.
  • Ms. Heather Harte-Hall M.Sc.
    Chief Compliance Officer
  • Ms. Martha O'Connor
    Chief HR Officer













CABA Stock - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CABA shares.
View CABA analyst ratings
or view top-rated stocks.

What is Cabaletta Bio's stock price forecast for 2023?

5 Wall Street research analysts have issued 1-year target prices for Cabaletta Bio's shares. Their CABA share price forecasts range from $10.00 to $18.00. On average, they anticipate the company's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 40.4% from the stock's current price.
View analysts price targets for CABA
or view top-rated stocks among Wall Street analysts.

How have CABA shares performed in 2023?

Cabaletta Bio's stock was trading at $9.25 at the beginning of the year. Since then, CABA stock has increased by 9.1% and is now trading at $10.09.
View the best growth stocks for 2023 here
.

When is Cabaletta Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CABA earnings forecast
.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) posted its earnings results on Thursday, March, 16th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05.

What ETFs hold Cabaletta Bio's stock?

ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV).

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

What is Cabaletta Bio's stock symbol?

Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (13.62%), Commodore Capital LP (6.22%), Jennison Associates LLC (2.65%), Perceptive Advisors LLC (2.31%), BlackRock Inc. (0.79%) and Geode Capital Management LLC (0.75%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am.
View institutional ownership trends
.

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cabaletta Bio's stock price today?

One share of CABA stock can currently be purchased for approximately $10.09.

How much money does Cabaletta Bio make?

Cabaletta Bio (NASDAQ:CABA) has a market capitalization of $316.42 million. The company earns $-52,970,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How can I contact Cabaletta Bio?

Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The official website for the company is www.cabalettabio.com. The company can be reached via phone at 267-759-3100 or via email at investors@cabalettabio.com.

This page (NASDAQ:CABA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -